Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Business
MarketBeat

MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push

MBX Biosciences (NASDAQ:MBX) used its Obesity Day event to outline preliminary clinical data for its lead obesity candidate MBX 4291, introduce a new preclinical obesity program and reiterate key development milestones across its endocrine and metabolic disease pipeline.

President and CEO Kent Hawryluk said the company is focused on once-weekly canvuparatide and its expanding obesity portfolio, which is built on MBX’s proprietary Precision Endocrine Peptide, or PEP, technology. He said the company has $440 million in cash, which it expects will fund operations into 2029.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.